Minimally Immunogenic Variants of SDR-Grafted Humanized Antibody CC49 and Their Use
Description of Invention:
Tumor Associated Glycoprotein 72 (TAG)-72 is an oncofetal antigen expressed on a majority of human carcinomas, including colorectal, gastric, pancreatic, breast, lung, and ovarian. The murine monoclonal antibody (mAb) CC49 specifically recognizes TAG-72 and has a higher affinity for TAG-72 than its predecessor, B72.3.
The present invention relates to humanized monoclonal antibodies that have high binding affinity for the tumor-associated glycoprotein (TAG)-72 with minimal immunogenicity. This anti-TAG-72 antibody binds to the same epitope as the CC49 murine variant developed at the National Cancer Institute. The variants of CC49 described in this patent application have been shown to have a decreased immune response, with comparable binding affinity, than the parent murine antibodies.
These variants have potential benefits for use in the detection and/or treatment of a range of human carcinomas. Certain fields of use may not be available. Please contact OTT for information regarding the availability of specific fields of use.
Patent Status:
DHHS Reference No. E-323-2003/0 --
U.S. Provisional Application No. 60/493,903 filed 29 Aug 2003
PCT Application No. PCT/US04/28004 filed 27 Aug 2004
Relevant Publication:
This variant was published in Kashmiri et al., “Minimizing Immunogenicity of the SDR-grafted Humanized Antibody CC49 by Genetic Manipulation of the Framework Residues,” Molecular Immunology, 40 (2003), 337-349.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-MAb Based Cancer -Diagnostics-In Vivo-MAb Cancer -Diagnostics Cancer -Therapeutics Cancer -Research Materials
For Additional Information Please Contact: Michelle A. Booden Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)451-7337
Email: boodenm@mail.nih.gov
Fax: (301) 402-0220
